Patents for Our Five Top Selling Products1
This disclosure is intended to simplify the activity of locating our patents documenting the scientific breakthroughs that these products represent. The patent table below lists patents currently in force that appear on the product virtual label, are cited in the 2023 10-K report, are cited in the Orange Book, and/or are cited in the Purple Book for our five top selling products1:
Product Proprietary/(Proper) Name |
Patent Number |
General Subject Matter |
1. Enbrel® (etanercept) |
US 11,491,223; US 10,307,483 |
Formulations and methods of preparing formulations |
US 8,063,182 |
Fusion protein and pharmaceutical compositions |
|
US 8,163,522 |
DNA encoding fusion protein and methods of making fusion protein |
|
2. Prolia® and 3. XGEVA® (denosumab)*
|
US 7,364,736 |
RANKL antibodies, including sequences |
US 7,427,659 |
Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction |
|
US 7,928,205 |
Methods for refolding of recombinant antibodies |
|
US 9,012,178 |
Methods of culturing mammalian cells to express protein in a serum free medium |
|
US 9,133,493 |
Methods of culturing mammalian cells |
|
US 9,228,168 |
Methods of stabilizing feed media |
|
US 9,320,816 |
Methods of treating cell culture media |
|
US 9,328,134 |
Methods of making proteins with modified glycosylation profile |
|
US 9,359,435 |
Methods of modulating glycoform content |
|
US 9,388,447 |
Independent tyrosine feed |
|
US 9,481,901 |
Methods of influencing high mannose glycoform content |
|
US 10,167,492 |
Methods of influencing fucosylated glycan content |
|
US 10,513,723 |
Methods of influencing high mannose glycoform content |
|
US 10,583,397 |
Systems and methods to control filtration |
|
US 10,822,630 |
Methods of influencing fucosylated glycan content |
|
US 10,894,972 |
Methods of influencing high mannose glycoform content |
|
US 11,077,404 |
Systems and methods to control filtration |
|
US 11,098,079 |
Methods of using a charged depth filter |
|
US 11,130,980 |
Methods of regulating high mannose glycoform content |
|
US 11,254,963 |
Methods of influencing high mannose glycoform content |
|
US 11,299,760 |
Methods of regulating high mannose glycoform content |
|
US 11,434,514 |
methods of influencing high mannose glycoform content |
|
US 11,459,595 |
Methods for increasing mannose content of recombinant proteins |
|
US 11,952,605 |
Methods for increasing mannose content of recombinant proteins |
|
US 8,460,896 |
Host cells and culture methods |
|
US 11,786,866 |
Process control systems and methods for use with filters and filtration processes |
|
US 11,744,950 |
Controlled dispense syringe |
|
US 11,685,772 |
Mammalian cell culture |
|
US 11,634,476 |
Mammalian cell culture |
|
US 11,427,848 |
Methods for harvesting mammalian cell cultures |
|
US 11,384,378 |
Methods for harvesting mammalian cell cultures |
|
US 11,292,829 |
Mammalian cell culture |
|
US 10,907,186 |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
|
US 10,655,156 |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
|
US 10,421,987 |
Methods for increasing mannose content of recombinant proteins |
|
US 8,247,210 |
Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
|
US 7,662,930 |
Polishing steps used in multi-step protein purification processes |
|
US 8,680,248 |
Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
|
US 10,106,829 |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
|
US 10,227,627 |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
|
US 11,275,090 |
Quantitation of glycan moiety in recombinant glycoproteins |
|
US 11,319,568 |
Methods for increasing mannose content of recombinant proteins |
|
US 11,486,883 |
Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
|
US 11,946,085 |
Methods for increasing mannose content of recombinant proteins |
|
US 8,053,236 |
Feed media |
|
US 7,888,101 |
Host cells comprising alpha 1,2 mannosidase and culture methods thereof |
|
EP 1 409 016 |
RANKL antibodies, including sequences |
|
4. Otezla® (apremilast) |
US 7,427,638 |
Composition and compound |
US 9,872,854; |
Methods of treatment |
|
5. Repatha® (evolocumab) |
US 8,030,457 |
Antibodies |
US 9,045,547 |
Methods of treatment |
|
EP 2 215 124 |
Compositions |
|
EP 2 707 029 |
Methods of treatment |
|
EP 2 844 285 |
Formulations |
|
US 8,563,698 |
Antibodies |
|
US 8,829,165 |
Antibodies |
|
US 8,859,741 |
Antibodies |
|
US 8,871,914 |
Antibodies |
|
US 8,883,983 |
Antibodies |
|
US 8,889,834 |
Antibodies |
|
US 8,981,064 |
Antibodies |
|
US 9,056,915 |
Antibodies |
|
US 9,493,576 |
Antibodies |
*Prolia and XGEVA are brand names for denosumab, but differ in indications.
1. Based on our publicly reported sales as disclosed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 14, 2024. We completed our acquisition of Horizon Therapeutics, plc on October 6, 2023, and our Annual Report on Form 10-K for the year ended December 31, 2023 includes product sales for the period from the Horizon Therapeutics acquisition date through December 31, 2023. We are providing this information as of November 1, 2024.